Systolic Heart failure treatment with

the If inhibitor ivabradine Trial

Clinical profiles and outcomes of patients

with chronic heart failure and chronic

obstructive pulmonary disease: efficacy

and safety of ivabradine.

A SHIFT study analysis

www.shift-study.comTavazzi L, et al. Int J Cardiol. 2013. Dec 10;170(2):182-188

Effect of ivabradine on composite of CV death or HF hospitalization

00 6 12 18 24

10

20

30

40

50

5

15

25

35

45

Pati

en

ts (

%)

Time (months)

COPD (ivabradine)

Non-COPD (ivabradine)

COPD (placebo)

Non-COPD (placebo)

Ivabradine is safe and effective in lowering the relative risk of the primary composite end point in both COPD and non-COPD patients

Tavazzi L et al. Int J Cardiol. 2013. Dec 10;170(2):182-188 www.shift-study.com